Pulse Biosciences Inc. [NASDAQ: PLSE] stock went on an upward path that rose over 8.37% on Friday, amounting to a one-week price increase of more than 2.01%. The company report on January 12, 2021 that Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress.
Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced CellFX® System regulatory progress updates.
Recent CellFX System Highlights.
Over the last 12 months, PLSE stock rose by 89.85%. The average equity rating for PLSE stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $630.13 million, with 25.22 million shares outstanding and 12.76 million shares in the current float. Compared to the average trading volume of 97.81K shares, PLSE stock reached a trading volume of 185455 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Pulse Biosciences Inc. [PLSE]:
H.C. Wainwright have made an estimate for Pulse Biosciences Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 12, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $26 to $6. The new note on the price target was released on February 14, 2020, representing the official price target for Pulse Biosciences Inc. stock. Previously, the target price had yet another raise to $27, while H.C. Wainwright analysts kept a Buy rating on PLSE stock.
The Average True Range (ATR) for Pulse Biosciences Inc. is set at 1.76 The Price to Book ratio for the last quarter was 20.72, with the Price to Cash per share for the same quarter was set at 1.27.
PLSE Stock Performance Analysis:
Pulse Biosciences Inc. [PLSE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.01. With this latest performance, PLSE shares gained by 46.41% in over the last four-week period, additionally plugging by 136.11% over the last 6 months – not to mention a rise of 89.85% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PLSE stock in for the last two-week period is set at 68.01, with the RSI for the last a single of trading hit 67.65, and the three-weeks RSI is set at 68.09 for Pulse Biosciences Inc. [PLSE]. The present Moving Average for the last 50 days of trading for this stock 18.79, while it was recorded at 24.96 for the last single week of trading, and 12.60 for the last 200 days.
Insight into Pulse Biosciences Inc. Fundamentals:
Return on Total Capital for PLSE is now -92.41, given the latest momentum, and Return on Invested Capital for the company is -90.51. Return on Equity for this stock declined to -96.78, with Return on Assets sitting at -83.46. When it comes to the capital structure of this company, Pulse Biosciences Inc. [PLSE] has a Total Debt to Total Equity ratio set at 21.86. Additionally, PLSE Total Debt to Total Capital is recorded at 17.94, with Total Debt to Total Assets ending up at 16.03. Long-Term Debt to Equity for the company is recorded at 21.86, with the Long-Term Debt to Total Capital now at 17.94.
Reflecting on the efficiency of the workforce at the company, Pulse Biosciences Inc. [PLSE] managed to generate an average of -$572,817 per employee.Pulse Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.10 and a Current Ratio set at 5.10.
PLSE Stock EPS
With the latest financial reports released by the company, Pulse Biosciences Inc. posted -0.66/share EPS, while the average EPS was predicted by analysts to be reported at -0.61/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -8.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PLSE.
Pulse Biosciences Inc. [PLSE] Insider Position Details
There are presently around $78 million, or 11.70% of PLSE stock, in the hands of institutional investors. The top three institutional holders of PLSE stocks are: BLACKROCK INC. with ownership of 887,238, which is approximately -0.725% of the company’s market cap and around 46.10% of the total institutional ownership; VANGUARD GROUP INC, holding 639,853 shares of the stock with an approximate value of $17.24 million in PLSE stocks shares; and NORTHERN TRUST CORP, currently with $6.8 million in PLSE stock with ownership of nearly -2.444% of the company’s market capitalization.
Positions in Pulse Biosciences Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 14 institutional holders increased their position in Pulse Biosciences Inc. [NASDAQ:PLSE] by around 72,268 shares. Additionally, 23 investors decreased positions by around 111,205 shares, while 14 investors held positions by with 2,707,036 shares. The mentioned changes placed institutional holdings at 2,890,509 shares, according to the latest SEC report filing. PLSE stock had 0 new institutional investments in for a total of 0 shares, while 3 institutional investors sold positions of 58,763 shares during the same period.